Kabra drugs Limited has announced a board meeting scheduled for April 21, 2026, at its Chennai corporate office to deliberate on significant corporate governance and business expansion matters. The meeting, convened under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, will address key strategic decisions for the pharmaceutical company.

Board Composition and Leadership Changes

The primary agenda item involves the appointment of Ms. Monam Kapoor (DIN: 09278005) as Additional Director, designated as Non-Executive and Independent Director of the company. This appointment represents a significant addition to the board's independent oversight capabilities and governance structure.

Business Diversification Strategy

The board will discuss comprehensive amendments to the Main Objects clause of the Memorandum of Association (MOA) to facilitate business diversification across multiple sectors. The proposed amendments encompass six distinct business verticals:

• Defence and Technology: Drones and defence equipment manufacturing and distribution
• Healthcare Expansion: Hospital, e-pharmacy, and medical equipment manufacturing and distribution
• Food and Beverages: All types of dairy products manufacturing
• Technology Solutions: Artificial Intelligence (AI) technologies, software, and hardware products manufacturing
• Hospitality Services: Hospitality and allied service sectors
• Agriculture: Establishing and running agro farms, manufacturing and trading of all kinds of agro products

Postal Ballot and Governance Procedures

The meeting will address several procedural matters related to shareholder approval processes:

Meeting Logistics

The board meeting is scheduled for April 21, 2026, at the company's corporate office in Chennai. The formal intimation was communicated to BSE Limited on April 10, 2026, by Managing Director Nanjappan Aravind (DIN: 01895602), ensuring compliance with regulatory disclosure requirements.

The comprehensive agenda reflects Kabra Drugs Limited's strategic vision to expand beyond its traditional pharmaceutical operations into diverse business sectors while strengthening its governance framework through independent board oversight.

Kabra drugs Limited has submitted its quarterly compliance certificate to BSE Limited, confirming adherence to SEBI regulations regarding dematerialization of securities for the quarter ended 31st March 2026. The pharmaceutical company filed the mandatory certificate pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Certificate Details

The certificate was issued by Skyline Financial Services Pvt Ltd, which serves as the company's Registrar and Share Transfer Agent. The document confirms that the company has properly handled the dematerialization process for physical share certificates received during the quarter.

Dematerialization Process Confirmation

The certificate confirms two critical compliance aspects for the dematerialization process:

• Securities Listing Verification: The securities comprised in the certificates have been properly listed on the stock exchange where the company's previously issued securities are traded
• Certificate Processing: Physical certificates have been duly verified, mutilated, and cancelled, with the depository's name substituted in records as the registered owner within the mandated 15-day timeframe

Corporate Information

Kabra Drugs Limited, incorporated under CIN L02423MP1989PLC005438, maintains its registered office at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh. The compliance certificate was signed by Nanjappan Aravind, Managing Director (DIN: 02040505), and authenticated by Parveen Sharma, Authorised Signatory from Skyline Financial Services Private Limited.

Regulatory Significance

This quarterly filing represents standard regulatory compliance under SEBI's depositories framework, ensuring transparency in the conversion process from physical to electronic securities. The timely submission demonstrates the company's commitment to maintaining proper corporate governance standards and regulatory adherence in securities management.